Journal ArticleDOI
Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening?
Reads0
Chats0
TLDR
It is hoped that ongoing prospective screening trials will determine the value of PSA screening, because there is no definitive proof that it decreases prostate cancer death rates, and there is concern that it may detect a significant number of clinically insignificant cancers.Abstract:
Prostate-specific antigen (PSA) has become one of the most commonly used cancer clinical tests, and routine PSA-based screening has led to a dramatic increase in prostate cancer detection. A significant downward stage migration has resulted, and a decrease in prostate cancer mortality has also been observed. However, PSA screening remains controversial because there is no definitive proof that it decreases prostate cancer death rates, and there is concern that it may detect a significant number of clinically insignificant cancers. Screening age and interval have been recently questioned, and the best threshold to recommend biopsy has been complicated by new data showing that prostate cancer exists at all PSA levels, even those thought to be “normal” in the past. It is hoped that ongoing prospective screening trials will determine the value of PSA screening. However, until these results are available the controversy will continue, and men will continue to be screened.read more
Citations
More filters
Journal ArticleDOI
Why 3-D? Gel-based microarrays in proteomics
TL;DR: 3‐D immobilization is compared with mainstream technologies based on surface immobilization and applications of biochips in the studies of protein interactions with other proteins, nucleic acids, and glycans are described.
Journal ArticleDOI
Effects of a High Dose, Aglycone-Rich Soy Extract on Prostate-Specific Antigen and Serum Isoflavone Concentrations in Men With Localized Prostate Cancer
Ralph W deVere White,Alexander Tsodikov,Eschelle C. Stapp,Stephanie E. Soares,Hajime Fujii,Robert M. Hackman +5 more
TL;DR: Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer.
Journal ArticleDOI
Racial differences in PSA screening interval and stage at diagnosis
William R. Carpenter,Daniel L. Howard,Yhenneko J. Taylor,Louie E. Ross,Sara E. Wobker,Paul A. Godley +5 more
TL;DR: More frequent or systematic PSA screening may be a pathway to reducing racial differences in prostate cancer stage at diagnosis, and, by extension, mortality.
Journal ArticleDOI
Erectile function in prostate cancer-free patients who underwent prostate saturation biopsy.
TL;DR: Although saturation biopsy of the prostate is a safe procedure on the basis of erectile function, the minimal risk of temporary postbiopsy ED should be discussed with previously potent patients.
Journal ArticleDOI
Surgery Illustrated--focus on details. Modified posterior reconstruction of the rhabdosphincter: application to robotic-assisted laparoscopic prostatectomy.
Geoff Coughlin,Pankaj P. Dangle,Nilesh Patil,Kenneth J. Palmer,Jill Woolard,Cathy Jensen,Vipul R. Patel +6 more
TL;DR: Robotic-assisted laparoscopic prostatectomy (RALP) is being performed more frequently as a treatment for presumed localized prostate cancer, with urologists now frequently treating younger men with organ-confined disease, who have good preoperative urinary and sexual function.
References
More filters
Journal ArticleDOI
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
Ian M. Thompson,Donna K. Pauler,Phyllis J. Goodman,Catherine M. Tangen,M. Scott Lucia,Howard L. Parnes,Lori M. Minasian,Leslie G. Ford,Scott M. Lippman,E. David Crawford,John Crowley,Charles A. Coltman +11 more
TL;DR: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range.
Journal ArticleDOI
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
William J. Catalona,Deborah S. Smith,Timothy L. Ratliff,Kathy M. Dodds,Douglas E. Coplen,Jerry J.J. Yuan,John A. Petros,Gerald L. Andriole +7 more
TL;DR: The combination of measurement of the serum PSA concentration and rectal examination, with ultrasonography performed in patients with abnormal findings, provides a better method of detecting prostate cancer thanrectal examination alone.
Journal ArticleDOI
American Cancer Society guidelines for the early detection of cancer.
TL;DR: Recommendations for the “cancer‐related check‐up,” in which clinical encounters provide case‐finding and health counseling opportunities, and an update of the most recent data pertaining to participation rates in cancer screening by age, gender, and ethnicity from the Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System and National Health Interview Survey.
Journal ArticleDOI
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Joseph E. Oesterling,Steven J. Jacobsen,Christopher G. Chute,Harry A. Guess,Cynthia J. Girman,Laurei A. Panser,Michael M. Lieber +6 more
TL;DR: The influence of patient age and prostatic size on the serum PSA concentration was assessed in order to use PSA more appropriately to detect clinically significant prostate cancer at an early, potentially curable stage.
Journal ArticleDOI
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
H. Ballentine Carter,Jay D. Pearson,E. Jeffrey Metter,Larry J. Brant,Larry J. Brant,Daniel W. Chan,Reubin Andres,Reubin Andres,James L. Fozard,Patrick C. Walsh +9 more
TL;DR: The most significant factor affecting serum PSA levels with age is the development of prostate disease, and rate of change in PSALevels may be a sensitive and specific early clinical marker for theDevelopment of prostate cancer.